Biogen Inks Deal with MAKScientific - Analyst Blog NASDAQ Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Biogen has also been pretty active on the deal-making/acquisition front so far in 2012. |
